Participated · Series A · Feb 2022

CoreMap develops a proprietary electrophysiology mapping system that combines high-density electrical data acquisition with sophisticated analytical software to generate detailed electrical activation maps of atrial fibrillation. The platform is designed to help electrophysiologists identify arrhythmia sources more accurately during catheter ablation procedures. CoreMap plans to use the new capital to accelerate product development and move the technology closer to commercial availability. The company believes improved mapping can address persistent clinical challenges in AF treatment and support more targeted procedural decision-making. Founded in 2016 and headquartered in Burlington, Massachusetts, CoreMap is positioning itself to compete in the expanding electrophysiology market with strategic backing from Medtronic following the Series C financing.

Participated · Series A · Jul 2021

Sweetch is an Israeli company that builds an AI-driven behavior-change app which analyzes smartphone “lifeprint” data to deliver hyper-personalized, emotionally intelligent reminders. The app times messages and modulates tone to increase the likelihood users follow clinical advice, and is distributed via partnerships with healthcare organizations, pharma, payers and providers rather than as an open app. Sweetch reports "tens of thousands of users" and about 45% of patients remain active after 24 months. In a 55-person prediabetes trial run at two Johns Hopkins Clinical Research Network sites, participants who completed the three-month study increased physical activity by an average of 2.8 MET-hours, lost ~1.6 kg, and reduced A1c by ~0.1%. The company has received NIH grant support to continue testing against gold-standard interventions and plans upcoming randomized controlled trials. Sweetch says it will use the Series A proceeds to expand into the U.S. and Brazil, grow its user base, and further tailor recommendations for additional conditions. Sweetch offers a patent-pending mobile app that assesses individuals' diabetes risk with a conversion time horizon and uses algorithms to guide users to the key objectives of the Diabetes Prevention Program. The product is intended for people at risk of developing diabetes or those who may be undiagnosed. Sweetch aligns its guidance with the clinically validated diet and exercise regimen associated with the Diabetes Prevention Program. The company planned to participate in a pilot study at Johns Hopkins Medicine in the first quarter of the year. The recent financing will support Sweetch's ambition to go to market in the U.S. and to be prescribed by doctors there, leveraging the Centers for Medicare and Medicaid decision to provide reimbursement for DPP participants. Leadership includes CEO Dana Chanan, CMO and business development lead Dr. Yossi Bahagon, and CTO Dan Lichtenfeld.

Participated · Series C · Feb 2021

Carevive's platform links clinical data with patient-reported outcomes to enable remote symptom management, tailor cancer care programs, and reduce patients' trips to health centers. The company says its software and analytics help researchers design cancer care delivery models, support payers' reimbursement decisions, and assist life-science companies developing personalized therapies. Carevive PROmpt® is its remote patient management functionality and the company reports deployment in dozens of hospitals across the U.S.; it was selected by Pfizer as the first Patient-Reported Outcomes (PRO) challenge winner for that product. Founded in 2013, Carevive emphasizes building real-world evidence through its Oncology Pragmatic Trial Investigator Network (Carevive OPT-IN®) to evaluate patient experiences. The company appointed Bruno Lempernesse as CEO in December 2020. Following the Series C, Carevive plans investments in technology, data analytics, infrastructure, expanded remote patient management, and growth of its OPT-IN network to build stronger evidence for treatment and symptom pathways.

Participated · Equity · Apr 2020

CyberMDX builds a cyber‑intelligence platform that inventories and manages hospitals' network‑connected assets and devices and monitors threats in real time. The company focuses on securing medical devices and improving hospital network security. Its research arm has discovered vulnerabilities in widely used medical devices and protocols, prompting a Homeland Security alert. CyberMDX was founded four years ago and is based in New York. The company raised $20 million in its latest financing and said it will use the proceeds to roll out its platform across new geographies and markets. Management framed the timing as important given the strain hospitals face from the COVID‑19 pandemic and said the platform can help support the healthcare community. CyberMDX provides a non-intrusive cybersecurity platform that delivers zero-touch visibility, risk management, and threat prevention and detection for medical devices and clinical networks (IoMT). The company focuses on protecting critical hospital assets such as MRIs, patient monitors and infusion pumps that often run legacy, unpatched systems. Its multidisciplinary team includes veterans of Israeli intelligence cyber units, medical device experts, and AI academic leaders; founders named in the article are Amir Magner and Moti Shniberg. CyberMDX emphasizes a scalable, easy-to-deploy solution to ensure operational continuity, patient safety and data protection. The company announced a $10 million Series A led by Pitango Venture Capital with participation from OurCrowd Qure and plans to expand its medical cybersecurity offering to hospitals worldwide.

Participated · Equity · May 2018

BrainQ builds a cloud-connected home therapy system that uses EEG-informed, low-intensity magnetic field (ELF-EMF) stimulation to target stroke-affected neural networks and accelerate neuroplastic recovery. The product is a whole-brain cylindrical headset paired with a back/hip pack, a tablet app, and a telemedicine/caregiver workflow for at‑home use. Treatment sessions last about an hour during which patients perform exercises while the headset streams EEG data to BrainQ’s cloud to generate personalized stimulation parameters. A small 25-patient study reported that 92% of treated patients saw major improvements over therapy alone and 80% achieved what the article described as recovery, results that supported FDA Breakthrough Device designation. The Breakthrough status also confers qualification for Medicare coverage and could enable shipment within a year or two. BrainQ raised $40 million to advance commercialization and run a larger clinical study. BrainQ develops personalized electromagnetic treatment protocols for stroke victims and patients with spinal cord injuries by analyzing patients' brainwaves. The company uses AI and claims to own one of the largest BCI-based EEG databases for motor tasks, which it says enables tailored therapies. At the time of the article, BrainQ was running two human clinical trials for stroke patients in Israel and working with Google’s Launchpad Accelerator. The team includes former members of Israeli elite intelligence units and academics with AI and neuroscience backgrounds. Financially, BrainQ announced a $5.3 million financing on top of a prior $3.5 million raise. The company says it plans to push its technology, expand operations, and position itself as a leader in BCI-based precision medicine. BrainQ develops a non-surgically embedded EEG system to gather neural data and aid recovery for stroke and spinal cord injury patients. The company is conducting two human clinical trials for stroke patients in Israel and must gain FDA approval before selling services in the U.S. A spokesperson said BrainQ will likely enter other markets first while awaiting U.S. regulatory clearance and hopes to be available in the U.S. by 2020. The startup has plans to expand into Alzheimer’s research and potentially children’s syndromes. BrainQ faces competition from implant-focused firms like Kernel and Neuralink as well as EEG-based competitors such as NeuroLutions and NeuroPace. Google’s Launchpad Studio worked with the company, and BrainQ has presented clinical findings to the World Congress of Neuro Rehabilitation. Financially, BrainQ has raised about $3.5 million to date from various Israeli investors and angel backers.